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ABSTRACT
We analyzed whole exome sequencing data in germline DNA from 412 high grade 
serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and 
identified 5,517 genes harboring a predicted deleterious germline coding mutation in 
at least one HGSOC case. Gene-set enrichment analysis showed enrichment for genes 
involved in DNA repair (p = 1.8x10-3). Twelve DNA repair genes - APEX1, APLF, ATX, EME1, 
FANCL, FANCM, MAD2L2, PARP2, PARP3, POLN, RAD54L and SMUG1 – were prioritized 
for targeted sequencing in up to 3,107 HGSOC cases, 1,491 cases of other epithelial 
ovarian cancer (EOC) subtypes and 3,368 unaffected controls of European origin. We 
estimated mutation prevalence for each gene and tested for associations with disease 
risk. Mutations were identified in both cases and controls in all genes except MAD2L2, 
where we found no evidence of mutations in controls. In FANCM we observed a higher 
mutation frequency in HGSOC cases compared to controls (29/3,107 cases, 0.96 percent; 
13/3,368 controls, 0.38 percent; P=0.008) with little evidence for association with other 
subtypes (6/1,491, 0.40 percent; P=0.82). The relative risk of HGSOC associated with 
deleterious FANCM mutations was estimated to be 2.5 (95% CI 1.3 – 5.0; P=0.006). In 
summary, whole exome sequencing of EOC cases with large-scale replication in case-
control studies has identified FANCM as a likely novel susceptibility gene for HGSOC, 
with mutations associated with a moderate increase in risk. These data may have clinical 
implications for risk prediction and prevention approaches for high-grade serous ovarian 
cancer in the future and a significant impact on reducing disease mortality.
INTRODUCTION
The genetic architecture of inherited susceptibility to 
epithelial ovarian cancer (EOC) is complex and pathogenic 
mutations in multiple DNA repair genes have now been 
shown to be associated with risk. These genes include 
BRCA1 and BRCA2  [1, 2], the mismatch repair genes 
[3, 4], RAD51C  [5, 6], RAD51D  [7] and BRIP1  [8]. 
The risk alleles of these genes are rare in the population 
and confer ovarian cancer risks ranging from moderate 
(average risk by age 80 of 5 percent) to high (average risk 
by age 80 of 50 percent). In addition to rare susceptibility 
alleles, multiple, common, susceptibility alleles with weak 
effects have also been identified [9–18]. The known risk 
alleles explain less than 50 percent of the inherited genetic 
component of ovarian cancer risk [19] suggesting that other 
susceptibility alleles exist but are yet to be identified. It is 
likely that the genetic architecture of this so-called missing 
heritability is made up of a combination of common, 
uncommon and rare alleles with weak or moderate effects.
Ovarian cancer is a heterogeneous disease with five 
main sub-types – high-grade serous, low-grade serous, 
endometrioid, clear cell and mucinous - and the genetic 
and clinical characteristics of the different subtypes are 
distinct. There are also differences in the basis of germline 
genetic predisposition for the different ovarian cancer 
subtypes, which reflects in their underlying biology. For 
example, susceptibility to high-grade serous ovarian cancer 
(HGSOC) is driven by mutations in genes that are involved 
in DNA double strand break repair (BRCA1, BRCA2, 
BRIP1, RAD51D and RAD51C), and as a consequence 
these tumors are highly genomically unstable. Ovarian 
cancers that are associated with Lynch syndrome, which 
are caused by mutations in the mismatch repair genes, are 
more likely to be endometrioid and clear cell subtypes and 
are karyotypically less complex than HGSOCs.
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One of the few successful advances in reducing 
mortality from EOC over the last 20 years has occurred 
as a result of identifying genes that increase disease risk. 
The clinical utility of testing for BRCA1/BRCA2 mutations 
is well-established; prophylactic bilateral salpingo-
oophorectomy plus/minus hysterectomy in carriers is now 
commonly used to reduce the risk of EOC and is offered to 
mutation carriers who have completed their families. The 
recent identification of RAD51C, RAD51D and BRIP1 as 
susceptibility genes for HGSOC raises the possibility that 
these genes too may have utility for risk prediction and 
clinical intervention.
The advent of next generation sequencing technologies 
provides opportunities for both the discovery of novel 
candidate susceptibility genes and their rapid replication 
in large sample sizes to confirm their role in disease 
predisposition. The prevalence of commercially available 
gene testing panels is also enabling rapid clinical translation 
of new genes that are identified from these research studies. 
The aim of this study was to identify genes with uncommon 
or rare deleterious coding mutations associated with HGSOC 
using a combination of germline, whole exome sequencing 
data from HGSOC cases analyzed by TCGA for discovery, 
followed by candidate-gene, targeted sequencing in a multi-
center EOC case-control study for replication.
RESULTS
TCGA exome sequencing data and selection of 
candidate genes
We identified 5,517 genes that harbored predicted 
deleterious germline coding sequence mutations in at least 
one of 412 HGSOC cases (≥0.24 percent) (Supplementary 
Table 2a and 2b). Based on gene-set enrichment analysis, 
genes in the DNA repair pathway were the most 
significantly enriched for protein truncating mutations 
(normalized enrichment = 1.86 fold, p = 1.8x10-3, FDR = 
0.26, see Supplementary Table 3). This pathway includes 
several confirmed ovarian cancer susceptibility genes and 
we identified deleterious mutations in all 5 homologous 
recombination DNA repair genes known to be associated 
with predisposition to high-grade serous ovarian cancer: 36 
in BRCA1 (8.7 percent), 26 in BRCA2 (6.3 percent), 2 in 
RAD51C (0.49 percent), 2 in RAD51D (0.49 percent) and 
3 in BRIP1 (0.73 percent) (Supplementary Table 4). Other 
significantly enriched pathways include ‘Response To 
Endogenous Stimulus’ (1.75 fold, p = 2.7x10-3, FDR = 0.23), 
‘Cellular Lipid Metabolism’ (1.72 fold, p =3.5x10-3, FDR = 
0.21), ‘Lipid Biosynthesis’ (1.85 fold, p = 4.2 x10-3, FDR = 
0.16), ‘Response to DNA Damage Stimulus’ (1.73 fold, p = 
4.8x10-3, FDR = 0.22) and ‘Fatty Acid Metabolism’ (1.78 
fold, p = 8.3x10-3, FDR = 0.26) (Supplementary Table 4).
Genes were prioritized for replication analysis in 
HGSOC cases and controls based on the following criteria: 
(1) The presence a deleterious germline mutation in at least 
one HGSOC case in exome sequencing data from TCGA 
analysis: (2) Their known or predicted role in DNA repair 
pathways shown to be involved in the development of high 
grade serous ovarian cancers, specifically base excision 
repair (BER), homologous recombination (HR), Fanconi 
Anemia (FANC); DNA polymerase beta (DNAP) and 
Poly (ADP-ribose) polymerase (PARP) pathways; (3) The 
frequency of somatic alterations in primary ovarian tumors 
identified in candidate genes from the TCGA and Cosmic 
databases, including the frequencies of somatic coding 
mutations, homozygous deletions involving candidate 
genes and loss of heterozygosity (LOH) at the gene locus. 
Based on these analyses we selected APEX1, APLF, APTX, 
EME1, FANCL, FANCM, MAD2L2, PARP2, PARP3, POLN, 
RAD54L and SMUG1 for targeted sequencing (Table 2).
Association of truncating mutations in candidate 
genes and high-grade serous ovarian cancer
After quality control analysis and exclusion of samples 
from participants of non-European origin, sequencing 
information for the coding region and splice site boundaries 
of the 12 candidate genes was available for 2,210 high-
grade serous cases, 924 other cases and 3,368 controls. 
Sequencing information was also available for four of the 
genes - APLF, APTX, FANCM and PARP2 - in an additional 
807 high-grade serous cases and 567 cases of other subtypes. 
The characteristics of these individuals by study are 
summarized in Table 1. We identified predicted-truncating, 
germline mutations (nonsense, frameshift indels or splice site 
alterations) in both cases and controls in 11 genes; only in 
MAD2L2 did we find no evidence of truncating mutations 
in controls. The frequency of mutations varied between 
genes. For example, in APLF we identified mutations in 
2.9 percent of cases and 3.7 percent of controls, while in 5 
genes - APEX1, APTX, EME1, MAD2L2 and SMUG1 - we 
identified mutations in less than 0.2 percent in both cases and 
controls (Table 2 & Supplementary Table 5).
We observed a higher frequency of mutations in 
FANCM in high-grade serous cases compared to controls 
(29/3,107 cases, 0.96 percent; 13/3,368 controls, 0.38 
percent; P=0.008). The frequency of FANCM mutations in 
cases of the other sub-types was similar to that of controls 
(6/1,491, 0.40 percent; p=0.82), although the difference in 
frequency between high-grade serous and other cases was not 
statistically significant (P=0.14). The mean age of diagnosis 
in FANCM mutation carriers with HGSOC was 61.4 years 
compared to 60.3 years in non-carriers. We estimated the 
relative risk of ovarian cancer associated with deleterious 
mutations in the FANCM gene as the odds ratio (OR), using 
data from the case-control studies that were not family 
based. The relative risk of HGSOC was 2.5 (95% confidence 
interval (CI) 1.3 – 5.0; P=0.006) with no increase in risk for 
other subtypes (OR = 0.89, 95% CI 0.32 – 2.5; P=0.82). The 
relative risk for all histologic subtypes of invasive epithelial 
ovarian cancer was 2.1 (95% 1.1 – 3.9; P=0.029).
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Table 1: Characteristics of ovarian cancer case-control populations analyzed in this study
Study Country Controls Cases
Number Mean age 
(range)
Number Mean age 
(range)
High-grade 
serousd
(%) Stage 
3/4
(%)d
AOC Australia 629 57 (20-80) 589 61 (23-80) 516 (88) 515 (88)
CAMc UK 0 NA 325 64 (19-90) 196 (60) 237 (79)
GRRa USA 0 NA 124 49 (21-83) 50 (40) NA
HJO/
HMO
Germany/
Belarus 519 36 (18-68) 341 58 (18-88) 107 (32) 153 (45)
ICNc UK 0 NA 422 57 (24-79) 293 (69) 31 (86)
LAX USA 209 62 (34-90) 175 62 (32-88) 175 (100) 159 (92)
MAY USA 660 63 (26-93) 650 64 (23-91) 630 (97) 581 (89)
RMHb UK 0 NA 61 53 (27-73) 61 (100) NA
SEA UK 835 53 (29-66) 700 57 (24-74) 349 (50) 388 (70)
SROc UK 0 NA 627 57 (18-84) 318 (51) 507 (81)
STA USA 147 48 (20-64) 151 53 (23-64) 116 (77) 111 (74)
UKO UK 369 65 (52-78) 353 61 (25-90) 267 (75) 242 (72)
Total 3,368 55 (18-93) 4,508 59 (18-91) 3,017 (67) 2,924 (81)
All studies are case-control studies except for: a familial ovarian cancer registry study, b case only hospital study and c case 
only clinical trial; d % of those with known stage
Table 2: Frequency of somatic and germline mutations in 12 candidate susceptibility genes in 412 high-grade serous 
ovarian cancer cases from TCGA and germline mutations in up to 4,508 ovarian cancer cases and 3,368 controls
Gene Somatic variants 
(412 TCGA cases)
Germline mutations
Mutationa 
N (%)
LOHb 
(%)
TCGA cases 
N (%)
HG serous 
cases (%)
Other cases 
N (%)
Controls 
N (%)
P-valuec 
N=2,210 N=924 N=3,368
APEX1 2 (0.49) 29 1 (0.24) 1 (0.03) 2 (0.13) 3 (0.09) 0.52
EME1 0 52 1 (0.24) 3 (0.10) 1 (0.07) 3 (0.09) 0.91
FANCL 2 (0.49) 10 1 (0.24) 18 (0.60) 8 (0.54) 28 (0.83) 0.34
MAD2L2 1 (0.24) 34 2 (0.49) 1 (0.03) 0 0 -
PARP3 1 (0.24) 31 1 (0.24) 6 (0.20) 1 (0.07) 13 (0.39) 0.22
POLN 1 (0.24) 42 3 (0.73) 15 (0.50) 10 (0.67) 26 (0.77) 0.09
RAD54L 2 (0.49) 12 1 (0.24) 4 (0.13) 1 (0.20) 6 (0.18) 0.80
SMUG1 0 18 1 (0.24) 2 (0.07) 1 (0.07) 2 (0.06) 0.71
N=3,107 N=1,491 N=3,368
APLF 2 (0.49) 10 5 (1.21) 92 (3.1) 40 (2.7) 121 (3.6) 0.16
APTX 2 (0.49) 40 1 (0.24) 4 (0.13) 4 (0.27) 4 (0.12) 0.97
FANCM 2 (0.49) 41 1 (0.24) 29 (0.96) 6 (0.40) 13 (0.39) 0.008
PARP2 1 (0.24) 30 1 (0.24) 4 (0.13) 3 (0.20) 5 (0.15) 0.65
a germline mutation
b Loss of heterozygosity
c Comparison of high-grade serous cases with controls
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FANCM mutations were broadly clustered into 
two regions. The first was an approximately 2kb region 
(nucleotides 446-2578) in and around a DEAH helicase 
domain at the N-terminus of the gene, which harbors 12/19 
of the different mutations we identified. The remaining 
seven different mutations were located in a region spanning 
almost 1kb between nucleotides 4853 and 5791 and a 
C-terminal degenerate ERCC4-like domain (Figure 1, 
Table 2 & Supplementary Table 6). However, there was 
little evidence that the distribution of FANCM mutations in 
cases along the gene differed from that in controls (P=0.60). 
The C-terminus nonsense variant c.C5791T was recurrent, 
occurring in 13 cases (0.29 percent) and 7 controls (0.21 
percent). N-terminal and C-terminal truncating variants 
in susceptibility genes (e.g. K3326* variant in BRCA2; 
6218delC variant in APC) have been shown to be associated 
with lower disease penetrance compared to truncating 
mutations elsewhere in the same gene [28, 29]. We therefore 
evaluated the association of FANCM mutations with 
HGSOC after re-classifying carriers of c.C5791T as non-
deleterious. The relative risk for more proximal mutations 
was 3.6 (95% CI 1.4 – 9.5; P=0.010), suggesting that 
c.C5791T may also be associated with a smaller risk.
In addition to truncating deleterious mutations, 
we also identified 627 different rare (less than 1 percent 
frequency) non-synonymous coding variants in these 
genes (Supplementary Table 7). Of these 243 are predicted 
to be damaging by at least two of the three function 
prediction programs Polyphen-2, Provean and SIFT; 
there was no difference in the frequency of uncommon 
variants in cases compared to controls for any of the 
genes evaluated based on the rare admixture maximum 
likelihood test (Supplementary Table 8).
DISCUSSION
We have carried out a comprehensive evaluation 
of germline coding sequence variation throughout the 
coding transcriptome in 412 HGSOC cases to identify 
candidate susceptibility genes associated with this 
subtype of disease. We used the targeted sequencing 
analysis of ovarian cancer cases and unaffected controls of 
European ancestry to establish the prevalence of predicted 
deleterious mutations in 12 genes involved in DNA repair. 
We found evidence that protein truncating mutations in 
FANCM are associated with an increased risk of HGSOC 
(P=0.008) with little evidence for an association for other 
subtypes (P=0.82). The increased risk for HGSOC is 
consistent with its functional interaction with BRCA1/
BRCA2 in homologous recombination and double strand 
DNA repair [4, 30]. It has recently been suggested that 
P<10-4 is a reasonable threshold for evaluating the 
association of rare, protein-truncating variants in candidate 
genes [31]. Assuming a population prevalence of 0.38%, 
as found in our controls, 6,100 cases and 6,100 controls 
would be required to detect an OR of 3 at this type 1 error 
rate with 80 percent power. Although such samples sizes 
are now feasible, more modest effects would need much 
larger samples sizes; for example 18,100 cases and 18,100 
controls to detect an OR of 2. The NHLBI GO Exome 
Sequencing Project has generated exome sequencing data 
on over 6,000 individuals from multiple studies carried out 
in the USA (http://evs.gs.washington.edu/EVS/). Of these 
4,300 individuals are of European ancestry, of whom 16 
carry a protein truncating variant in FANCM which is a 
similar frequency to that in our controls (frequency 0.37 
percent). If these samples are used as additional controls 
for the US samples the association with high-grade serous 
ovarian cancer becomes more significant (P=0.001) yet 
they do not reach the nominal threshold for significance 
of P<10-4. Further support for our findings comes from 
a Finnish study that reported a significant association 
for FANCM Q1701X with triple negative breast cancer 
[32]. While a significant association with ovarian 
cancer was not reported, the frequency of this nonsense 
variant was higher in ovarian cancer cases than controls 
Figure 1: Distribution of predicted deleterious mutations in the FANCM gene in ovarian cancer cases and controls 
with respect to both the translated protein and the exonic architecture of the coding sequence. Black lines indicate 
mutations identified in cases only; blue lines indicate mutations detected both cases and controls. No mutations were identified in controls 
only. Where a mutation was identified in more than one subject, the number of times the mutation was detected is given in brackets.
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(OR = 1.6, 95% CI 0.75 – 3.2, P = 0.23). However, this 
study had limited power to detect an association because 
of the modest sample size (number of cases = 548) 
with power further reduced by including all subtypes of 
ovarian cancer.
The prevalence of truncating mutations in APEX1, 
APLF, ATX, EME1, FANCL, MAD2L2, PARP2, PARP3, 
POLN, RAD54L and SMUG1 in controls was very low 
with little evidence for an increased frequency in cases. 
It is therefore unlikely that these genes contribute 
substantially to ovarian cancer risk, but we cannot rule 
out that deleterious mutations in any one of these genes 
are associated with modest risks. The fact that truncating 
mutations in these genes were identified in controls 
highlights the need for caution in interpreting the findings 
of sequencing studies carried out in case series without 
appropriate controls. This is particularly important given 
the common practice of including such genes on gene 
sequencing panels that are used in clinical practice [31].
It is likely that we have underestimated the true 
prevalence of deleterious variants in these genes in 
cases and controls. Our sequencing method did not 
provide complete sequence coverage of each gene in 
all samples (mean coverage 90 to 97 percent in cases 
and controls) and so some mutations may have been 
missed. Furthermore, the PCR enrichment used for 
sequencing library preparation does not enable the 
detection of large genomic deletions and rearrangement 
mutations. Finally, we did not include missense variants 
in our prevalence or risk estimates because we cannot be 
certain of their pathogenicity in the absence of definitive 
functional assays.
If the association of FANCM protein truncating 
mutations is confirmed, FANCM mutation analysis could 
be rapidly implemented as part of a program of clinical 
genetic testing followed by prophylactic surgery (salpingo-
oophorectomy). However, the clinical utility in testing 
unaffected women for FANCM mutations is unclear from 
the risk estimates. The “best” estimate (the point estimate) 
of the relative risk is equivalent to a lifetime risk of 
invasive epithelial ovarian cancer of 3.8 percent, although 
the true risk may be lower than this given the uncertainty 
of the risk estimate. It has been suggested that 80 percent 
confidence limits on cumulative risk estimates are more 
appropriate for clinical decision-making. These are shown 
in Figure 2A. The cumulative risk is also likely to be 
modified by the presence of other lifestyle and genetic 
risk factors. The log-additive model on a relative risk scale 
for interaction between risk factors has been shown to fit 
well for interactions between risk alleles and lifestyle risk 
factors. Eighteen common risk alleles for ovarian cancer 
have now been identified [9–11, 14–16, 18]. Women with 
FANCM mutations at the 80th centile of the polygenic 
risk distribution based on the 18 known common risk 
alleles [9–18] would have an expected lifetime risk of 
4.6 percent (80% CI 3.1 – 7.0, Figure 2B), assuming that 
this log-additive model also applies to FANCM carriers. 
Incorporating other EOC risk factors, specifically oral 
contraceptive pill use, tubal ligation, parity, a history of 
endometriosis and family history increases the lifetime 
risk at the 80th centile of the risk distribution to 5.2 percent 
(80% CI 3.4 – 7.8, Figure 2C). FANCM mutation testing 
in women with HGSOC might also have clinical utility 
through targeted treatment with Poly (ADP-ribose) 
polymerase (PARP) inhibitors, which are currently being 
evaluated in women with BRCA1 and BRCA2 associated 
ovarian cancer.
Gene-set enrichment analysis of genes with at least 
one protein truncating mutation in the TCGA HGSOC 
cases showed a statistically significant enrichment for 
genes involved in ‘DNA Repair’ processes. This is perhaps 
not surprising given the critical role of double strand DNA 
repair in the initiation and development of HGSOCs, and 
its contribution to the chromosomal instability of this 
Figure 2: Estimated cumulative risk of epithelial ovarian cancer in women with a germline truncating mutation in 
FANCM: Black line – population risk based on UK incidence data for 2009. Blue line – estimated risk to FANCM carriers 
(dashed lines 80% confidence limits): A. average risks; B. risks to FANCM carriers at the 80th centile of a polygenic risk distribution based 
on 18 known common risk alleles; C. risks to FANCM carriers at the 80th centile of a risk distribution based on 18 known common risk 
alleles together with known lifestyle risk factors.
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tumor subtype. FANCM adds to a growing list of DNA 
repair associated genes (BRCA1, BRCA2, RAD51C, 
RAD51D and BRIP1) that confer susceptibility to 
HGSOC. We also observed significant enrichment for 
genes in biosynthesis and metabolic pathways including 
cellular lipid metabolism, lipid biosynthesis and fatty 
acid metabolism. It is known that ovarian cancer cells 
migrate to the adipocyte-rich omentum and recent reports 
show that lipids are transferred from omental adipocytes 
to ovarian cancer cells, where they are metabolised 
and accelerate tumorigenesis [33]. These findings are 
consistent with recent data suggesting that ovarian cancer 
cells undergo a metabolic shift during tumorigenesis to 
become more dependent on lipid metabolism as an energy 
source [34]. Genes in these pathways may represent a new 
class of ovarian cancer susceptibility genes, but is will 
require large case-control targeted sequencing analyses 
similar to those described in the current study to confirm 
this.
In summary, we have found reasonable evidence 
that deleterious germline mutations in FANCM are 
associated with a moderate increase in the risk of 
high-grade serous epithelial ovarian cancer but are not 
associated with non-serous disease subtypes. Predicted 
deleterious mutations in the other 11 candidate genes 
we identified from TCGA whole exome analysis do 
not appear to predispose to ovarian cancer. This study 
highlights the critical need for accurate risk estimation 
of candidate susceptibility genes based on very large 
sample sizes before genes of moderate penetrance have 
clinical utility in cancer prevention.
MATERIALS AND METHODS
TCGA germline exome sequencing data analysis
Data were collected by the TCGA project as 
described elsewhere (http://cancergenome.nih.gov/). 
We received approval from the TCGA data access 
committee to access and analyze the germline exome 
sequencing data from HGSOC cases. Sequence data 
for 412 cases were downloaded from the online NIH 
facility, dbGaP, as BAM files. We used the Samtools 
sequence analysis software [20] for the manipulation 
and analysis of the BAM files. The Samtools pileup 
function was used to assemble and quantify sequence 
variation in each sample. Then ANNOVAR was used to 
annotate the sequence variation detected. We classified 
all variants predicted to result in truncation of the 
protein (frameshift indels, nonsense substitutions and 
consensus splice site variants) as potentially deleterious 
variants. We only carried forward variants having a 
depth of at least 40 and an alternative allele ratio of 
at least 30 percent. Common variants with a minor 
allele frequency of >5 percent were excluded from 
the analysis. A finalised set of uncommon deleterious 
variants identified was tabulated for every RefSeq 
gene with a mature mRNA structure, i.e. having an 
NM type accession identifier. We identified 8,275 
unique, uncommon, deleterious variants in 5,517 genes 
occurring a total of 16,969 times in 412 cases (see 
Supplementary file DeleteriousVariants.xls for details).
Lymphocyte DNA for 341 of the TCGA samples 
were also genotyped using the Illumina Omni1M 
genotyping array. We used these data to estimate the 
accuracy of the calling of substitutions by comparing 
the called genotypes based on the NGS data with 
the genotype calls from the TCGA SNP genotyping. 
Concordance for 1.96M genotypes was 99.0 percent. No 
equivalent data are available to evaluate the quality of 
indel calling.
Study subjects
We carried out targeted sequencing of 12 candidate 
genes selected using the results from the TCGA data 
analysis (see results) in 2,385 high-grade serous cases 
and 3,569 controls. These were from 8 ovarian cancer 
case-control studies (AOC, HJO, HMO, LAX, MAY, 
SEA, STA, UKO), 1 familial ovarian cancer registry 
from the USA (GRR) and 1 case series (RMH). These 
studies have been described previously (e.g [15]). We 
also selected 988 cases with other tumour histologies 
(Table 1) as some common alleles that predispose to 
HGSOC are also associated with an increased risk 
of other subtypes. All studies had ethics committee 
approval, and all participants provided written, informed 
consent.
In addition we sequenced four of the genes of 
interest (APLF, APTX, FANCM and PARP2) in another 
859 high grade serous cases and 609 cases of other sub-
types from the SCOTROC (SRO), ICON7 (ICN) and 
OV04 (CAM) ovarian cancer clinical trials.
Targeted gene sequencing
Target sequence enrichment was performed using 
48.48 Fluidigm access arrays and 4-primer chemistry 
for addition of barcode and adapter sequences during 
the PCR amplification. Target sequence amplicons were 
200bp or smaller for complete sequencing using 100 bp 
pair-end sequencing on the Illumina HiSeq2000 according 
to the manufacturer’s protocol (Illumina Inc, San Diego, 
CA). A total of 314 amplicons were designed and the 
average fragment size was 187 base pairs (range 150-200) 
(Supplementary Table 1).
Sequenced reads were de-multiplexed using 
standard Illumina software. We used the Burrows-Wheeler 
Aligner (BWA) [21] for sequencing read alignment 
against the human genome reference sequence (hg19). 
The Genome Analysis Toolkit (GATK) [22] was used for 
base quality-score recalibration, local insertion/deletion 
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(indel) realignment, and substitution/indel discovery. 
Variants were only considered for further analysis if 
they satisfied the set of recommended GATK filters as 
applicable to our data and as described in the GATK best 
practices guide. ANNOVAR [23] was used to annotate 
the sequence variation detected. The transcript identifiers 
used for mutation annotation of the 12 genes are detailed 
in Supplementary Table 1.
Variant alternate allele frequency was defined 
as the fraction of alternate allele bases compared 
to the total number of bases at the variant locus. We 
applied the following thresholds for variants calling: 
the minimum coverage is 15, a variant will be called 
if (1) coverage ≥500 and alternate allele frequency 
≥10 percent, or (2) 250 ≤coverage <500 and alternate 
allele frequency ≥15 percent, or (3) 30 ≤coverage 
<250 and alternate allele frequency ≥20 percent, or 
(4) 15 ≤coverage <30 and alternate allele frequency 
≥30 percent. The thresholds for coverage and alternate 
allele frequency used in variant calling were defined 
previously based on results from sequencing of positive 
controls with known variants.
We excluded 202 cases and 56 controls from further 
analyses because <80 percent of the target bases from 
these samples had read depth ≥15. The average coverage 
of coding region and splice sites screened at 15X depth for 
the remaining samples (up to 8,070) were: 95.9 percent 
for APEX1; 95.0 percent for APLF; 97.0 percent for 
APTX; 97.1 percent for EME1; 97.9 percent for FANCL; 
95.8 percent for FANCM; 95.7 percent for MAD2L2; 93.9 
percent for PARP2; 94.9 percent for PARP3; 94.7 percent 
for POLN; 97.4 percent for RAD54L; and 98.4 percent for 
SMUG1.
Deleterious mutation identification and 
validation
Deleterious variants were defined as those 
predicted to result in protein truncation (frameshift, 
splice site and nonsense mutations). We used the 
programme MaxEntScan to identify splice site variants 
most likely to affect gene splicing [24]. Splice site 
variants with a MaxEntScan score that differed from 
the score for the consensus sequence by more than 40 
percent were assumed to affect splicing. Sequencing 
alignments were visually inspected using the Integrative 
Genomic Viewer (IGV) [25] to confirm presence of 
deleterious variants. We performed Sanger sequencing 
using standard methods for validation in independent 
PCR products of all potentially deleterious truncating 
variants and all potentially deleterious non-synonymous 
variants.
Statistical methods
We carried out a pathway analysis to identify sets 
of genes most likely to harbour truncating mutations in 
the 412 HGSOC cases in TCGA. We excluded mutations 
that occurred in more than 8 out of 412 cases (MAF > 
0.5%). We ranked all genes containing frameshift indels 
and nonsense substitutions (4,640 genes after removing 
189 open reading frames) in descending order of the 
number mutations per gene. To account for the possibility 
of genes with longer coding length containing a larger 
number of mutations simply due to their length and to 
break ties among genes containing the same number of 
mutations, we regressed the number of mutations on 
coding length and used the residuals as the actual ranking 
metric. A total of 249 pathways containing between 
15 and 500 genes from the Gene Ontology Biological 
Processes compendium were downloaded from the 
Molecular Signatures Database (v5.0) [26]. The ranked 
list of genes and the pathways were used for gene set 
enrichment analysis (GSEA; v2-2.2.2.0) run to 10,000 
permutations [26].
We tested for association between deleterious 
mutations and ovarian cancer risk using unconditional 
logistic regression adjusted for geographical region of 
origin (Australia, continental Europe, the United Kingdom 
and the USA). Odds ratios and associated 95 percent 
confidence intervals (95% CI) were also calculated.
We identified multiple missense variants that have 
an unknown functional effect on the proteins. We excluded 
all missense variants with a minor allele frequency of > 
1 percent from further analyses as large-scale genome-
wide association studies have shown that the relative risks 
conferred by common susceptibility allele are small (< 1.3) 
and thus unlikely to be detectable by the sample size of this 
study. The statistical power to detect single rare alleles by 
association, even if they confer larger risk (RR > 2) is still 
modest. We therefore used the rare admixture likelihood 
(RAML) burden test [27] to test for association on a gene-
by-gene basis. The RAML combines the information 
across multiple rare variants to increase statistical power 
and allows for alleles associated with either an increased 
or a decreased risk. We classified variants with frequency 
≤ 1 percent by whether or not they are predicted to have 
a damaging effect on protein function by more than one 
of the following prediction tools - SIFT (score <0.05), 
polyphen-2 (classified as probably damaging or damaging) 
and Provean (score<=-2.5). Only subjects with a call rate 
greater than 80 percent for missense variants and variants 
with a call rate greater than 80 percent with genotype 
frequencies consistent with Hardy-Weinberg equilibrium 
(P>10-5) were included in these analyses.
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